HK1251149A1 - L-鸟氨酸苯乙酸盐制剂 - Google Patents
L-鸟氨酸苯乙酸盐制剂 Download PDFInfo
- Publication number
- HK1251149A1 HK1251149A1 HK18110518.2A HK18110518A HK1251149A1 HK 1251149 A1 HK1251149 A1 HK 1251149A1 HK 18110518 A HK18110518 A HK 18110518A HK 1251149 A1 HK1251149 A1 HK 1251149A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ornithine phenylacetate
- liver
- patients
- oral formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150238P | 2015-04-20 | 2015-04-20 | |
| US201562150238P | 2015-04-20 | ||
| US201562150676P | 2015-04-21 | 2015-04-21 | |
| US201562150676P | 2015-04-21 | ||
| US201562211619P | 2015-08-28 | 2015-08-28 | |
| US201562211619P | 2015-08-28 | ||
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US201562255300P | 2015-11-13 | ||
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| US201662276754P | 2016-01-08 | ||
| PCT/US2016/028298 WO2016172112A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1251149A1 true HK1251149A1 (zh) | 2019-01-25 |
Family
ID=57144228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18110518.2A HK1251149A1 (zh) | 2015-04-20 | 2016-04-19 | L-鸟氨酸苯乙酸盐制剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160338982A1 (https=) |
| EP (2) | EP3285756B1 (https=) |
| JP (2) | JP2018513171A (https=) |
| KR (1) | KR20180006904A (https=) |
| CN (2) | CN107708684A (https=) |
| AU (2) | AU2016252382A1 (https=) |
| CA (1) | CA2983146C (https=) |
| DK (1) | DK3285756T3 (https=) |
| ES (1) | ES2944311T3 (https=) |
| HK (1) | HK1251149A1 (https=) |
| MX (2) | MX391167B (https=) |
| RU (1) | RU2755904C2 (https=) |
| WO (1) | WO2016172112A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG158073A1 (en) | 2004-11-26 | 2010-01-29 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| CA2757373C (en) | 2009-04-03 | 2018-05-08 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| EA201691430A1 (ru) | 2009-06-08 | 2017-02-28 | ЮСиЭл БИЗНЕС ПиЭлСи | Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата |
| US10039735B2 (en) | 2014-11-24 | 2018-08-07 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3337473A4 (en) | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| AU2016353350B2 (en) * | 2015-11-13 | 2021-09-23 | Ocera Therapeutics, Inc. | Formulation of L-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2018208677A1 (en) | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| IL296055A (en) | 2017-08-14 | 2022-10-01 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
| MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
| KR102852068B1 (ko) | 2019-05-09 | 2025-08-28 | 오세라 테라퓨틱스, 아이엔씨. | 간성 뇌증의 평가 및 치료 방법 |
| WO2021076709A1 (en) * | 2019-10-16 | 2021-04-22 | Ocera Therapeutics, Inc. | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2021152587A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Treating acute liver disease with tlr-mik inhibitors |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| SG158073A1 (en) | 2004-11-26 | 2010-01-29 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| CA2757373C (en) | 2009-04-03 | 2018-05-08 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EA201691430A1 (ru) * | 2009-06-08 | 2017-02-28 | ЮСиЭл БИЗНЕС ПиЭлСи | Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата |
| MX360062B (es) | 2010-10-06 | 2018-10-22 | Ocera Therapeutics Inc | Metodos de elaboracion de fenilacetato de l-ornitina. |
-
2016
- 2016-04-19 RU RU2017137643A patent/RU2755904C2/ru active
- 2016-04-19 DK DK16783692.3T patent/DK3285756T3/da active
- 2016-04-19 WO PCT/US2016/028298 patent/WO2016172112A1/en not_active Ceased
- 2016-04-19 EP EP16783692.3A patent/EP3285756B1/en active Active
- 2016-04-19 CN CN201680036045.1A patent/CN107708684A/zh active Pending
- 2016-04-19 CA CA2983146A patent/CA2983146C/en active Active
- 2016-04-19 ES ES16783692T patent/ES2944311T3/es active Active
- 2016-04-19 KR KR1020177032260A patent/KR20180006904A/ko not_active Ceased
- 2016-04-19 CN CN202110931620.7A patent/CN113599350A/zh active Pending
- 2016-04-19 HK HK18110518.2A patent/HK1251149A1/zh unknown
- 2016-04-19 MX MX2017013170A patent/MX391167B/es unknown
- 2016-04-19 JP JP2017554815A patent/JP2018513171A/ja active Pending
- 2016-04-19 AU AU2016252382A patent/AU2016252382A1/en not_active Abandoned
- 2016-04-19 EP EP23157390.8A patent/EP4205735A1/en not_active Withdrawn
- 2016-04-19 US US15/133,087 patent/US20160338982A1/en not_active Abandoned
-
2017
- 2017-10-12 MX MX2022003855A patent/MX2022003855A/es unknown
-
2021
- 2021-02-05 AU AU2021200740A patent/AU2021200740A1/en not_active Abandoned
- 2021-12-22 US US17/559,453 patent/US20220184014A1/en not_active Abandoned
-
2022
- 2022-03-23 JP JP2022046762A patent/JP2022101549A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017137643A3 (https=) | 2019-09-17 |
| JP2018513171A (ja) | 2018-05-24 |
| US20220184014A1 (en) | 2022-06-16 |
| US20160338982A1 (en) | 2016-11-24 |
| CN107708684A (zh) | 2018-02-16 |
| EP3285756A1 (en) | 2018-02-28 |
| ES2944311T3 (es) | 2023-06-20 |
| EP3285756B1 (en) | 2023-02-22 |
| RU2017137643A (ru) | 2019-05-20 |
| JP2022101549A (ja) | 2022-07-06 |
| CA2983146A1 (en) | 2016-10-27 |
| MX391167B (es) | 2025-03-11 |
| AU2016252382A1 (en) | 2017-11-02 |
| RU2755904C2 (ru) | 2021-09-22 |
| DK3285756T3 (da) | 2023-05-08 |
| CA2983146C (en) | 2023-09-12 |
| KR20180006904A (ko) | 2018-01-19 |
| AU2021200740A1 (en) | 2021-03-04 |
| CN113599350A (zh) | 2021-11-05 |
| EP4205735A1 (en) | 2023-07-05 |
| EP3285756A4 (en) | 2019-01-23 |
| MX2017013170A (es) | 2018-04-11 |
| MX2022003855A (es) | 2023-03-02 |
| WO2016172112A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251149A1 (zh) | L-鸟氨酸苯乙酸盐制剂 | |
| MA42950A (fr) | Administration d'agents de potentialisation de cftr modifiés au deutérium | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| PL3896064T3 (pl) | Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| HK1221256A1 (zh) | 用於调节mir-122的微小rna化合物和方法 | |
| MX2022001517A (es) | Formulaciones de fenilacetato de l-ornitina. | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| WO2012097116A3 (en) | Isotopologues of isoindole derivatives | |
| WO2013117744A3 (en) | Methods of treating fibrosis | |
| HK1221916A1 (zh) | 使用阿曲生坦用於改善脂质概况的方法 | |
| WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
| HK1217295A1 (zh) | 4'-疊氮基,3'-脫氧基-3'-氟取代的核苷衍生物 | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| WO2014204854A8 (en) | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids | |
| PH12022550738A1 (en) | Dosages and uses of ornithine phenylacetate for treating hyperammonemia | |
| WO2015079067A3 (en) | Various compounds as autophagy stimulants | |
| BR112015015855A2 (pt) | composições líquidas de stévia | |
| PH12018500895B1 (en) | Formulation of l-ornithine phenylacetate | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| MX377806B (es) | Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática. | |
| MX2020006173A (es) | Derivados glucosidicos de treprostinilo. | |
| Rojas et al. | Ultrasound and ethanol pre-treatments to improve drying and rehydration of pumpkin | |
| 이상용 | The Implications of the Amended Social Services Act for Social Welfare Corporations |